Drugs / CEA protein antigen
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02403505 | Dec 2021 → Nov 2026 expected | rectal cancer | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEA protein antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02403505 ↗ |
| Action | Activate | “Activate human CEA Protein Antigen Presentation Reaction.” NCT02403505 ↗ |
| Modality | Protein / enzyme biologic | “CEA protein antigen 0.05 mg plus BCG Organism 50 MG Mix” NCT02403505 ↗ |
| Route | Other | “By the percutaneous route with the multiple puncture device” NCT02403505 ↗ |